GSK has unveiled the data for its novel antibiotic gepotidacin as a treatment for gonorrhoea, putting the drug on track to become an important therapy for people with resistant forms
GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.
In an encouraging development for the fight against antimicrobial resistance (AMR), GSK's novel antibiotic gepotidacin has shown efficacy in two phase 3 trials, setting up regulatory filing
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.